Takeda executive sells shares to cover tax on awards

Takeda Pharmaceutical executive Teresa Marie Bitetti, President of OBU, reported selling 50,012 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per ADS.

Rhea-AI Filing Summary

Takeda Pharmaceutical executive Teresa Marie Bitetti, President of OBU, reported selling 50,012 American Depositary Shares on 2026-08-10 at a weighted average price of $17.10 per ADS. A footnote states this was a mandatory sale to cover taxes on vesting equity awards. She now directly holds 252,010 ADS.

Insider Trade Summary

Net Seller: 50,012 shares

Net Sell 1 txn

Insider Bitetti Teresa Marie

Role President, OBU

Sold 50,012 shs ($855K)

Type	Security	Shares	Price	Value
Sale	American Depositary Shares F1, F2	50,012	$17.10	$855K

Holdings After Transaction: American Depositary Shares — 252,010 shares (Direct)

Footnotes (2)

1. F1. Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person.
2. F2. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Key Figures

Shares sold: 50,012 American Depositary Shares Weighted average sale price: $17.10 per ADS Shares owned after transaction: 252,010 American Depositary Shares +1 more

4 metrics

Shares sold 50,012 American Depositary Shares Non-derivative sale on 2026-08-10 to cover taxes

Weighted average sale price $17.10 per ADS Price for the 50,012 American Depositary Shares sold

Shares owned after transaction 252,010 American Depositary Shares Direct holdings following the reported sale

Sale transactions reported 1 sale transaction Single non-derivative sale reported in the Form 4

Key Terms

American Depositary Shares, mandatory sale to cover taxes, weighted average price

3 terms

American Depositary Shares financial

"Represents <b>American Depositary Shares</b> of Takeda Pharmaceutical"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

mandatory sale to cover taxes financial

"Represents a <b>mandatory sale to cover taxes</b> associated with the vesting"

weighted average price financial

"The price reported in Column 4 is a <b>weighted average price</b>"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Takeda Pharmaceutical (TAK) report in this Form 4?

Takeda Pharmaceutical reported that executive Teresa Marie Bitetti sold 50,012 American Depositary Shares on 2026-08-10. The sale was tied to equity award vesting, with shares sold to cover related tax obligations.

At what price were the Takeda (TAK) shares sold by Teresa Marie Bitetti?

The shares were sold at a weighted average price of $17.10 per ADS. A footnote explains this price reflects multiple trades, and detailed breakdowns by execution price are available upon request from the issuer or the SEC staff.

Why did Teresa Marie Bitetti sell Takeda (TAK) shares according to the Form 4?

The filing states the transaction was a mandatory sale to cover taxes associated with the vesting of equity awards. This indicates the sale was driven by tax withholding requirements rather than a discretionary portfolio decision.

How many Takeda (TAK) shares does Teresa Marie Bitetti hold after the reported sale?

After the sale, Teresa Marie Bitetti directly holds 252,010 American Depositary Shares of Takeda Pharmaceutical. This post-transaction balance is disclosed in the Form 4 as the total shares beneficially owned following the transaction.

How many total shares did Teresa Marie Bitetti sell in this Takeda (TAK) Form 4 filing?

The Form 4 reports a single transaction in which 50,012 American Depositary Shares were sold. Transaction data show this is the only sale in the filing, resulting in net reported sales of the same share amount.

Was the Takeda (TAK) insider sale under a Rule 10b5-1 trading plan?

The filing does not indicate that the transaction was made under a Rule 10b5-1 trading plan. The 10b5-1 checkbox is not marked as an affirmatively adopted plan for this reported sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/12/2026 - 09:45 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bitetti Teresa Marie

(Last) (First) (Middle)

40 LANDSDOWNE STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
TAKEDA PHARMACEUTICAL CO LTD [ TAK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, OBU

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
American Depositary Shares	08/10/2026		S(1)		50,012	D	$17.1(2)	252,010	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a mandatory sale to cover taxes associated with the vesting of equity awards held by the Reporting Person.

2. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

	/s/ Samuel Ntonme, by power of attorney, for Teresa Bitetti	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)